Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62,921 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
Mahlangu J, Kaczmarek R, von Drygalski A, Shapiro S, Chou SC, Ozelo MC, Kenet G, Peyvandi F, Wang M, Madan B, Key NS, Laffan M, Dunn AL, Mason J, Quon DV, Symington E, Leavitt AD, Oldenburg J, Chambost H, Reding MT, Jayaram K, Yu H, Mahajan R, Chavele KM, Reddy DB, Henshaw J, Robinson TM, Wong WY, Pipe SW; GENEr8-1 Trial Group. Mahlangu J, et al. Among authors: wang m. N Engl J Med. 2023 Feb 23;388(8):694-705. doi: 10.1056/NEJMoa2211075. N Engl J Med. 2023. PMID: 36812433 Clinical Trial.
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity.
Mahlangu JN, Weldingh KN, Lentz SR, Kaicker S, Karim FA, Matsushita T, Recht M, Tomczak W, Windyga J, Ehrenforth S, Knobe K; adept™2 Investigators. Mahlangu JN, et al. J Thromb Haemost. 2015 Nov;13(11):1989-98. doi: 10.1111/jth.13141. Epub 2015 Oct 13. J Thromb Haemost. 2015. PMID: 26362483 Free article. Clinical Trial.
Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports.
Wang M, Álvarez-Román MT, Chowdary P, Quon DV, Schafer K. Wang M, et al. Blood Coagul Fibrinolysis. 2016 Oct;27(7):737-744. doi: 10.1097/MBC.0000000000000565. Blood Coagul Fibrinolysis. 2016. PMID: 27116081 Free PMC article. Review.
Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) study.
Kempton CL, Wang M, Recht M, Neff A, Shapiro AD, Soni A, Kulkarni R, Buckner TW, Batt K, Iyer NN, Cooper DL. Kempton CL, et al. Among authors: wang m. Patient Prefer Adherence. 2017 Sep 19;11:1603-1612. doi: 10.2147/PPA.S141389. eCollection 2017. Patient Prefer Adherence. 2017. PMID: 29033549 Free PMC article.
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Johnston SC, et al. N Engl J Med. 2018 Jul 19;379(3):215-225. doi: 10.1056/NEJMoa1800410. Epub 2018 May 16. N Engl J Med. 2018. PMID: 29766750 Free PMC article. Clinical Trial.
Focusing in on use of pharmacokinetic profiles in routine hemophilia care.
Croteau SE, Callaghan MU, Davis J, Dunn AL, Guerrera M, Khan O, Neufeld EJ, Raffini LJ, Recht M, Wang M, Iorio A. Croteau SE, et al. Among authors: wang m. Res Pract Thromb Haemost. 2018 May 27;2(3):607-614. doi: 10.1002/rth2.12118. eCollection 2018 Jul. Res Pract Thromb Haemost. 2018. PMID: 30046766 Free PMC article.
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jiménez-Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME. Young G, et al. Among authors: wang m. Blood. 2019 Dec 12;134(24):2127-2138. doi: 10.1182/blood.2019001869. Blood. 2019. PMID: 31697801 Free PMC article. Clinical Trial.
Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years.
Shapiro A, Chaudhury A, Wang M, Escobar M, Tsao E, Barnowski C, Feng J, Jain N, Quon DV. Shapiro A, et al. Among authors: wang m. Haemophilia. 2020 Nov;26(6):975-983. doi: 10.1111/hae.14152. Epub 2020 Oct 4. Haemophilia. 2020. PMID: 33012060 Free PMC article.
62,921 results
You have reached the last available page of results. Please see the User Guide for more information.